Deep Track Capital, LP
GREENWICH, CT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.94B2026 Q3+ $196.5M options (notional, not included)
Positions74
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.43.3%
What Changed This Quarter?
Top Holdings
GH
Guardant Health
8.2%
BMRN
Biomarin Pharmaceutical
6.2%
IMVT
Immunovant
5.0%
TARS
Tarsus Pharmaceuticals
4.9%
MANE
Veradermics
3.8%
VERA
Vera Therapeutics
3.7%
PCVX
Vaxcyte
3.3%
ALKS
Alkermes
3.0%
New / Increased
20 new · 17 increased
INSMNEW
Insmed
2.5%
TEMCALLNEW
Tempus Ai
1.3%
LTGONEW
Latigo Biotherapeutics
1.2%
BBIONEW
Bridgebio Pharma
0.9%
Attovia Thera…NEW
Attovia Therapeutics
0.9%
BMRN
Biomarin Pharmaceutical
6.2%
+92.7%
VERA
Vera Therapeutics
3.7%
+75.0%
UTHR
United Therapeutics
2.6%
+142.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.